^
    Back
    Association details:
    Biomarker:PBRM1 mutation
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cell Reports Medicine
    Title:

    Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

    Published date:
    02/21/2023
    Excerpt:
    PBRM1 mutation status (mutant vs. wild type) in this subset correlated with OS (HR, 95% CI: 0.33 [0.15–0.74], log rank test, p = 0.02).
    DOI:
    https://doi.org/10.1016/j.xcrm.2023.100947